# Standard Biotools Inc.: Form 10-Q for the period ended Sep 30, 2011

- Company: [Standard Biotools Inc.](/companies/lab.md) (CIK 1162194)
- Form: 10-Q
- Filed: 2011-11-14
- Accepted by EDGAR: Nov 14, 2011, 16:40 ET
- Period: 2011-09-30
- Accession: 0001193125-11-311107
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1162194/000119312511311107/d238398d10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1162194/000119312511311107/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2011-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2011-07-01 to 2011-09-30 | $10.6m | us-gaap:Revenues |
| Revenue | 9 months, 2011-01-01 to 2011-09-30 | $29.9m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2011-07-01 to 2011-09-30 | $3.3m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 9 months, 2011-01-01 to 2011-09-30 | $9.2m | us-gaap:CostOfGoodsSold |
| Research and development | 3 months, 2011-07-01 to 2011-09-30 | $3.3m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2011-01-01 to 2011-09-30 | $9.9m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2011-07-01 to 2011-09-30 | $8.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2011-01-01 to 2011-09-30 | $23.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2011-07-01 to 2011-09-30 | −$4.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2011-01-01 to 2011-09-30 | −$15.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2011-07-01 to 2011-09-30 | $439.0k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2011-01-01 to 2011-09-30 | $2.7m | us-gaap:InterestExpense |
| Income tax | 3 months, 2011-07-01 to 2011-09-30 | $20.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2011-01-01 to 2011-09-30 | $130.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2011-07-01 to 2011-09-30 | −$4.5m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2011-01-01 to 2011-09-30 | −$19.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2011-07-01 to 2011-09-30 | −$0.22 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months, 2011-01-01 to 2011-09-30 | −$1.70 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months, 2011-01-01 to 2011-09-30 | −$15.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2011-01-01 to 2011-09-30 | $997.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2011-09-30 | $11.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2011-09-30 | $76.0m | us-gaap:AssetsCurrent |
| Total assets | at 2011-09-30 | $82.6m | us-gaap:Assets |
| Current liabilities | at 2011-09-30 | $19.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2011-09-30 | $23.5m | us-gaap:Liabilities |
| Long-term debt | at 2011-09-30 | $3.0m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2011-09-30 | $8.6m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2011-09-30 | $59.2m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1162194/000119312511311107/d238398d10q.htm

Filed Nov 14, 2011.
Source: SEC EDGAR, the filing index for accession 0001193125-11-311107. Last ingested by Listed: Nov 5, 2026, 21:16 ET. No prices; not investment advice.
